EDC and the E-Clinical Space

Date: June 2007
Length: 00:12:14
Size: 5.60MB

Thought Leader: Ronald Kershner, Ph.D., Senior VP, Clinical Operations, inVentiv Clinical Solutions LLC

Dr. Kershner outlines the current state of play of EDC in the industry and the benefits the technology can bring to clinical studies, particularly access to real-time data and cost savings. Dr. Kershner also provides his insights to remaining adoption challenges.

Play Full Podcast

For more information on how you can be featured in a podcast, contact Dan Limbach at dlimbach@pharmavoice.com or call him at (847) 594-0157.

Why Validate?

Date: June 2007

Length: 00:11:39
Size: 5.33MB

Thought Leader: Chris Biddle, VP, Solutions Architecture, GHX Pharma Solutions

Good data validation practices for managed care can make a big impact on a pharmaceutical company's bottom line. This episode covers several important issues on this topic, including the general business environment for validation, why validation is important, Medicare Part D ramifications, primary causes of data errors, the ROI of validation, and more.

Play Full Podcast

For more information on how you can be featured in a podcast, contact Dan Limbach at dlimbach@pharmavoice.com or call him at (847) 594-0157.

Biological Drug Development

Date: June 2007

Length: 00:5:13
Size: 2.39MB

Thought Leader: William J. Newell, Executive VP, Aerovance

Mr. Newell discusses the uses of biologics in the development of asthma treatments, the challenges involved with biologic drug development, and considerations when designing a trial.

Play Full Podcast

For more information on how you can be featured in a podcast, contact Dan Limbach at dlimbach@pharmavoice.com or call him at (847) 594-0157.

Biotechnology Business Trends

Date: June 2007

Length: 00:6:19
Size: 2.89MB

Thought Leader: Kenneth C. Carter, Ph.D., President and CEO, Avalon Pharmaceuticals

Dr. Carter talks about technology trends in the emerging biotechnology space, deal-making at the preclinical level, and Avalon's technology, a high-throughput discovery and development engine that is based on the total breadth of a cell's response at the genomic level to a drug.

Play Full Podcast

For more information on how you can be featured in a podcast, contact Dan Limbach at dlimbach@pharmavoice.com or call him at (847) 594-0157.

Seed Funding

Date: June 2007
Length: 00:3:41
Size: 1.68MB

Thought Leader:Barbara Schilberg, CEO, BioAdvance, Biotechnology Greenhouse of SE Pennsylvania

Ms. Schilberg discusses why it's important to invest in a new generation of life-sciences companies and how her organization is addressing a national problem — the gap in seed funding.

Play Full Podcast

For more information on how you can be featured in a podcast, contact Dan Limbach at dlimbach@pharmavoice.com or call him at (847) 594-0157.

Global Biotechnology Trends

Date: June 2007
Length: 00:4:26
Size: 2.03MB

Thought Leader:Martyn Postle, Chairman and Chief Executive, Cambridge Healthcare & Biotech Ltd.

In this Podcast episode, Mr. Postle provides a top-line overview of global biotechnology trends based on results from a recent report — U.K. Drug Pipeline —completed by Cambridge Healthcare & Biotech.

Play Full Podcast

For more information on how you can be featured in a podcast, contact Dan Limbach at dlimbach@pharmavoice.com or call him at (847) 594-0157.

Partnerships and Funding Opportunities

Date: June 2007
Length: 00:5:09
Size: 2.36MB

Thought Leader:Lucienne Cicurel, Ph.D., External Affairs Director, Debiopharm Group

Dr. Cicurel discusses trends in competition in the oncology space, best practices for partnerships, and funding for development.

Play Full Podcast

For more information on how you can be featured in a podcast, contact Dan Limbach at dlimbach@pharmavoice.com or call him at (847) 594-0157.

Multimechanism Drugs

Date: June 2007
Length: 00:4:26
Size: 2.02MB

Thought Leader:James S. Burns, President and CEO, EntreMed Inc.

Mr. Burns talks about the advantages of multimechanism drugs to solve distinct development challenges in the oncology arena, the complexities of drug development, and the challenges associated with running a biotechnology company.

Play Full Podcast

For more information on how you can be featured in a podcast, contact Dan Limbach at dlimbach@pharmavoice.com or call him at (847) 594-0157.

The State of Biotechnology in Kansas

Date: June 2007
Length: 00:3:56
Size: 1.80MB

Thought Leader: U.S. Senator Pat Roberts, U.S. Senator, Kansas; Tom Thornton, President and CEO, Kansas Biotech Authority, and Angela Krupps, President, Kansas BIO

State representatives discuss Kansas' biotechnology initiatives — health, agro, and biofuels — and what these mean to the state's economy.

Play Full Podcast

For more information on how you can be featured in a podcast, contact Dan Limbach at dlimbach@pharmavoice.com or call him at (847) 594-0157.

Macromolecule Development Trends

Date: June 2007
Length: 00:6:47
Size: 3.10MB

Thought Leader:Timothy Duffy, Executive VP, Marketing and Business Development, Nastech Pharmaceutical Co.

Mr. Duffy discusses how macromolecules — peptides and protein therapeutics — are expanding opportunities for development, partnering, therapeutic focus, and delivery of compounds.

Play Full Podcast

For more information on how you can be featured in a podcast, contact Dan Limbach at dlimbach@pharmavoice.com or call him at (847) 594-0157.

New R&D Model

Date: June 2007
Length: 00:12:56
Size: 5.92MB

Thought Leader: Jeff Davis, Head, Global New Business Development, and Kevin Driscoll, Ph.D., Director, Global New Technology Development, P&G Pharmaceuticals Inc.

Mr. Davis and Dr. Driscoll reveal P&G's outsourcing strategy for drug development, therapeutic areas of concentration, partnering strategies, and how the biotechnology component factors into the model.

Play Full Podcast

For more information on how you can be featured in a podcast, contact Dan Limbach at dlimbach@pharmavoice.com or call him at (847) 594-0157.

Integrated Development Strategies

Date: June 2007
Length: 00:6:51
Size: 3.13MB

Thought Leader: Stephen Keith Rhind, Ph.D., Senior VP, S*BIO Pte Ltd.

Dr. Rhind talks about the advantages of having integrated development capabilities, being based in Singapore in terms of patient recruitment, and the challenges involved in moving from discovery to development from a commercial perspective.

Play Full Podcast

For more information on how you can be featured in a podcast, contact Dan Limbach at dlimbach@pharmavoice.com or call him at (847) 594-0157.

Hot Trends in the Biotech Sector

Date: June 2007
Length: 00:4:53
Size: 2.23MB

Thought Leader: Scott Ballenger, R.Ph., President, Trial Acceleration Institute

Mr. Ballenger discusses the hot trends in the biotech sector, such as the global nature of the industry, innovation, and what the promise of the industry holds.

Play Full Podcast

For more information on how you can be featured in a podcast, contact Dan Limbach at dlimbach@pharmavoice.com or call him at (847) 594-0157.